Literature DB >> 8275469

Percentage of embryonal carcinoma and of vascular invasion predicts pathological stage in clinical stage I nonseminomatous testicular cancer.

J W Moul1, W F McCarthy, E B Fernandez, I A Sesterhenn.   

Abstract

We analyzed 92 clinical stage I nonseminomatous testicular germ cell tumors for primary tumor histological factors that would distinguish true pathological stage I disease (N = 54) from those patients who harbored occult disease and actually were later found to have pathological stage II disease (N = 38). Primary tumor pathological material was analyzed for vascular invasion, lymphatic invasion, tunical invasion, and quantitative determination of percentage of the primary tumor composed of embryonal carcinoma, yolk sac carcinoma, teratoma, and seminoma. Univariate logistic regression analyses revealed that vascular invasion (P = 0.0001), percentage of embryonal carcinoma (P = 0.0001), lymphatic invasion (P = 0.0001), and tunical invasion (P = 0.0013) were higher in pathological stage II and that percentage of teratoma (P = 0.0001) and of yolk sac carcinoma (P = 0.0174) were higher in stage I. Percentage of seminoma was not significant. Individually, these parameters were able to correctly predict occult disease 66.3 to 80.4% of the time. In multivariate logistic regression analysis, only vascular invasion and percentage of embryonal carcinoma remained significant, and a model using these two variables was able to correctly predict stage 85.9% of the time. Vascular invasion and determination of percentage of embryonal carcinoma should be assessed for all clinical stage I nonseminomatous germ cell tumor patients and the model presented herein can be used clinically to predict the likelihood of occult disease and dictate therapy.

Entities:  

Mesh:

Year:  1994        PMID: 8275469

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  18 in total

1.  ZBTB16: a novel sensitive and specific biomarker for yolk sac tumor.

Authors:  Guang-Qian Xiao; Faqian Li; Pamela D Unger; Hani Katerji; Qi Yang; Loralee McMahon; David E Burstein
Journal:  Mod Pathol       Date:  2016-02-26       Impact factor: 7.842

Review 2.  Treatment of clinical stage I testicular cancer and a possible role for new biological prognostic parameters.

Authors:  C Bokemeyer; M A Kuczyk; J Serth; J T Hartmann; H J Schmoll; U Jonas; L Kanz
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

3.  Cost- and risk-benefit considerations in the management of clinical stage I nonseminomatous testicular tumors.

Authors:  J Baniel; B J Roth; R S Foster; J P Donohue
Journal:  Ann Surg Oncol       Date:  1996-01       Impact factor: 5.344

4.  Risk-adapted management for patients with clinical stage I non-seminomatous germ cell tumour of the testis.

Authors:  Soner Guney; Nese Guney; Nurettin Cem Sonmez; Erbil Ergenekon
Journal:  Med Oncol       Date:  2008-09-26       Impact factor: 3.064

Review 5.  High-risk clinical stage I nonseminomatous germ cell tumors: the case for chemotherapy.

Authors:  Dirk H Westermann; Urs E Studer
Journal:  World J Urol       Date:  2009-07-28       Impact factor: 4.226

Review 6.  Early-stage testis cancer.

Authors:  R S Foster
Journal:  Curr Treat Options Oncol       Date:  2001-10

7.  Cutaneous metastasis from testicular germ cell tumour.

Authors:  Anjana Joel; Amit Dilip Bhatt; Abraham Samuel; Raju Titus Chacko
Journal:  Indian J Urol       Date:  2014-01

8.  Mixed germ cell tumor of the testicle with ravdomuosarcomatous component: a case report.

Authors:  Konstantinos Stamatiou; Panagiotis Papadopoulos; Georgios Perlepes; Nikolaos Galariotis; Michalis Olympitis; Hippocrates Moschouris; Theodora Vasilakaki
Journal:  Cases J       Date:  2009-12-10

9.  Prognostic factors in patients with pathological stage I non-seminomatous testicular germ cell tumors and tumor recurrence during follow-up.

Authors:  P Albers; W T DeRiese; T M Ulbright; J P Donohue; R S Foster
Journal:  Urol Res       Date:  1995

10.  Whole-body FDG-PET in patients with stage I non-seminomatous germ cell tumours.

Authors:  U Lassen; G Daugaard; A Eigtved; L Højgaard; K Damgaard; M Rørth
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-01-09       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.